ID   OCRL_HUMAN              Reviewed;         901 AA.
AC   Q01968; A6NKI1; A8KAP2; B7ZLX2; O60800; Q15684; Q15774; Q4VY09;
AC   Q4VY10; Q5JQF1; Q5JQF2; Q9UJG5; Q9UMA5;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   07-JUN-2005, sequence version 3.
DT   10-MAY-2017, entry version 187.
DE   RecName: Full=Inositol polyphosphate 5-phosphatase OCRL-1;
DE            EC=3.1.3.36;
DE   AltName: Full=Lowe oculocerebrorenal syndrome protein;
GN   Name=OCRL; Synonyms=INPP5F, OCRL1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM B).
RC   TISSUE=Kidney;
RX   PubMed=1321346; DOI=10.1038/358239a0;
RA   Attree O., Olivos I.M., Okabe I., Bailey L.C., Nelson D.L.,
RA   Lewis R.A., McInnes R.R., Nussbaum R.L.;
RT   "The Lowe's oculocerebrorenal syndrome gene encodes a protein highly
RT   homologous to inositol polyphosphate-5-phosphatase.";
RL   Nature 358:239-242(1992).
RN   [2]
RP   SEQUENCE REVISION TO 585.
RA   Attree O., Olivos I.M., Okabe I., Bailey L.C., Nelson D.L.,
RA   Lewis R.A., McInnes R.R., Nussbaum R.L.;
RL   Submitted (MAR-2001) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND ALTERNATIVE SPLICING.
RC   TISSUE=Brain;
RX   PubMed=9048911; DOI=10.1007/s004390050329;
RA   Nussbaum R.L., Orrison B.M., Janne P.A., Charnas L.R., Chinault A.C.;
RT   "Physical mapping and genomic structure of the Lowe syndrome gene
RT   OCRL1.";
RL   Hum. Genet. 99:145-150(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM A).
RC   TISSUE=Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM B).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 814-843.
RX   PubMed=8504307; DOI=10.1093/hmg/2.4.461;
RA   Leahey A.-M., Charnas L.R., Nussbaum R.L.;
RT   "Nonsense mutations in the OCRL-1 gene in patients with the
RT   oculocerebrorenal syndrome of Lowe.";
RL   Hum. Mol. Genet. 2:461-463(1993).
RN   [9]
RP   CHARACTERIZATION.
RX   PubMed=7761412; DOI=10.1073/pnas.92.11.4853;
RA   Zhang X., Jefferson A.B., Auethavekiat V., Majerus P.W.;
RT   "The protein deficient in Lowe syndrome is a phosphatidylinositol-4,5-
RT   bisphosphate 5-phosphatase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:4853-4856(1995).
RN   [10]
RP   CHARACTERIZATION.
RX   PubMed=9430698; DOI=10.1074/jbc.273.3.1574;
RA   Zhang X., Hartz P.A., Philip E., Racusen L.C., Majerus P.W.;
RT   "Cell lines from kidney proximal tubules of a patient with Lowe
RT   syndrome lack OCRL inositol polyphosphate 5-phosphatase and accumulate
RT   phosphatidylinositol 4,5-bisphosphate.";
RL   J. Biol. Chem. 273:1574-1582(1998).
RN   [11]
RP   INTERACTION WITH APPL1; CLATHRIN; FAM109A AND FAM109B, SUBCELLULAR
RP   LOCATION, AND VARIANTS OCRL ASN-768 AND PRO-797.
RX   PubMed=20133602; DOI=10.1073/pnas.0914658107;
RA   Swan L.E., Tomasini L., Pirruccello M., Lunardi J., De Camilli P.;
RT   "Two closely related endocytic proteins that share a common OCRL-
RT   binding motif with APPL1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:3511-3516(2010).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   INTERACTION WITH APPL1; FAM109A AND FAM109B, VARIANT OCRL ASN-768, AND
RP   CHARACTERIZATION OF VARIANT OCRL ASN-768.
RX   PubMed=21233288; DOI=10.1091/mbc.E10-08-0730;
RA   Noakes C.J., Lee G., Lowe M.;
RT   "The PH domain proteins IPIP27A and B link OCRL1 to receptor recycling
RT   in the endocytic pathway.";
RL   Mol. Biol. Cell 22:606-623(2011).
RN   [14]
RP   FUNCTION IN CILIA ASSEMBLY, TISSUE SPECIFICITY, SUBCELLULAR LOCATION,
RP   INTERACTION WITH RAB8A, AND MUTAGENESIS OF ASP-422; ASP-499 AND
RP   PHE-668.
RX   PubMed=22543976; DOI=10.1093/hmg/dds163;
RA   Luo N., West C.C., Murga-Zamalloa C.A., Sun L., Anderson R.M.,
RA   Wells C.D., Weinreb R.N., Travers J.B., Khanna H., Sun Y.;
RT   "OCRL localizes to the primary cilium: a new role for cilia in Lowe
RT   syndrome.";
RL   Hum. Mol. Genet. 21:3333-3344(2012).
RN   [15]
RP   FUNCTION IN CILIOGENESIS.
RX   PubMed=22228094; DOI=10.1093/hmg/ddr615;
RA   Coon B.G., Hernandez V., Madhivanan K., Mukherjee D., Hanna C.B.,
RA   Barinaga-Rementeria Ramirez I., Lowe M., Beales P.L., Aguilar R.C.;
RT   "The Lowe syndrome protein OCRL1 is involved in primary cilia
RT   assembly.";
RL   Hum. Mol. Genet. 21:1835-1847(2012).
RN   [16]
RP   REVIEW.
RX   PubMed=22381590; DOI=10.1016/j.tibs.2012.01.002;
RA   Pirruccello M., De Camilli P.;
RT   "Inositol 5-phosphatases: insights from the Lowe syndrome protein
RT   OCRL.";
RL   Trends Biochem. Sci. 37:134-143(2012).
RN   [17]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH INPP5F AND RAB5A.
RX   PubMed=25869668; DOI=10.1083/jcb.201409064;
RA   Nakatsu F., Messa M., Nandez R., Czapla H., Zou Y., Strittmatter S.M.,
RA   De Camilli P.;
RT   "Sac2/INPP5F is an inositol 4-phosphatase that functions in the
RT   endocytic pathway.";
RL   J. Cell Biol. 209:85-95(2015).
RN   [18]
RP   STRUCTURE BY NMR OF 1-119, DOMAIN PH, INTERACTION WITH CLATHRIN, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=19536138; DOI=10.1038/emboj.2009.155;
RA   Mao Y., Balkin D.M., Zoncu R., Erdmann K.S., Tomasini L., Hu F.,
RA   Jin M.M., Hodsdon M.E., De Camilli P.;
RT   "A PH domain within OCRL bridges clathrin-mediated membrane
RT   trafficking to phosphoinositide metabolism.";
RL   EMBO J. 28:1831-1842(2009).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 540-678 IN COMPLEX WITH
RP   RAB8A.
RX   PubMed=21378754; DOI=10.1038/emboj.2011.60;
RA   Hou X., Hagemann N., Schoebel S., Blankenfeldt W., Goody R.S.,
RA   Erdmann K.S., Itzen A.;
RT   "A structural basis for Lowe syndrome caused by mutations in the Rab-
RT   binding domain of OCRL1.";
RL   EMBO J. 30:1659-1670(2011).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 564-901, SUBCELLULAR
RP   LOCATION, AND INTERACTION WITH APPL1.
RX   PubMed=17765681; DOI=10.1016/j.devcel.2007.08.004;
RA   Erdmann K.S., Mao Y., McCrea H.J., Zoncu R., Lee S., Paradise S.,
RA   Modregger J., Biemesderfer D., Toomre D., De Camilli P.;
RT   "A role of the Lowe syndrome protein OCRL in early steps of the
RT   endocytic pathway.";
RL   Dev. Cell 13:377-390(2007).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 536-901 IN COMPLEX WITH
RP   FAM109A.
RX   PubMed=21666675; DOI=10.1038/nsmb.2071;
RA   Pirruccello M., Swan L.E., Folta-Stogniew E., De Camilli P.;
RT   "Recognition of the F&H motif by the Lowe syndrome protein OCRL.";
RL   Nat. Struct. Mol. Biol. 18:789-795(2011).
RN   [22]
RP   VARIANTS OCRL THR-367 DEL; GLY-451; SER-463 AND ARG-524.
RX   PubMed=9199559; DOI=10.1086/515471;
RA   Lin T., Orrison B.M., Leahey A.-M., Suchy S.F., Bernard D.J.,
RA   Lewis R.A., Nussbaum R.L.;
RT   "Spectrum of mutations in the OCRL1 gene in the Lowe oculocerebrorenal
RT   syndrome.";
RL   Am. J. Hum. Genet. 60:1384-1388(1997).
RN   [23]
RP   VARIANTS OCRL TYR-375; GLN-500; ASP-508 AND CYS-513.
RX   PubMed=9682219; DOI=10.1006/mgme.1998.2687;
RA   Lin T., Orrison B.M., Suchy S.F., Lewis R.A., Nussbaum R.L.;
RT   "Mutations are not uniformly distributed throughout the OCRL1 gene in
RT   Lowe syndrome patients.";
RL   Mol. Genet. Metab. 64:58-61(1998).
RN   [24]
RP   VARIANTS OCRL GLN-500 AND GLN-524.
RX   PubMed=9632163;
RX   DOI=10.1002/(SICI)1096-8628(19980605)77:5<348::AID-AJMG2>3.0.CO;2-J;
RA   Kawano T., Indo Y., Nakazato H., Shimadzu M., Matsuda I.;
RT   "Oculocerebrorenal syndrome of Lowe: three mutations in the OCRL1 gene
RT   derived from three patients with different phenotypes.";
RL   Am. J. Med. Genet. 77:348-355(1998).
RN   [25]
RP   VARIANT OCRL ARG-522.
RX   PubMed=9788721;
RA   Kubota T., Sakurai A., Arakawa K., Shimazu M., Wakui K., Furihata K.,
RA   Fukushima Y.;
RT   "Identification of two novel mutations in the OCRL1 gene in Japanese
RT   families with Lowe syndrome.";
RL   Clin. Genet. 54:199-202(1998).
RN   [26]
RP   VARIANTS OCRL GLU-357; GLU-421; ASP-424 AND TYR-498.
RX   PubMed=10923037;
RX   DOI=10.1002/1098-1004(200008)16:2<157::AID-HUMU8>3.0.CO;2-9;
RA   Monnier N., Satre V., Lerouge E., Berthoin F., Lunardi J.;
RT   "OCRL1 mutation analysis in French Lowe syndrome patients:
RT   implications for molecular diagnosis strategy and genetic
RT   counseling.";
RL   Hum. Mutat. 16:157-165(2000).
RN   [27]
RP   VARIANTS OCRL LYS-478-479-TYR DEL; GLN-500 AND LEU-526.
RX   PubMed=10767176; DOI=10.1006/mgme.1999.2955;
RA   Roeschinger W., Muntau A.C., Rudolph G., Roscher A.A., Kammerer S.;
RT   "Carrier assessment in families with Lowe oculocerebrorenal syndrome:
RT   novel mutations in the OCRL1 gene and correlation of direct DNA
RT   diagnosis with ocular examination.";
RL   Mol. Genet. Metab. 69:213-222(2000).
RN   [28]
RP   VARIANTS DD2 CYS-318 AND CYS-479.
RX   PubMed=15627218; DOI=10.1086/427887;
RA   Hoopes R.R. Jr., Shrimpton A.E., Knohl S.J., Hueber P., Hoppe B.,
RA   Matyus J., Simckes A., Tasic V., Toenshoff B., Suchy S.F.,
RA   Nussbaum R.L., Scheinman S.J.;
RT   "Dent disease with mutations in OCRL1.";
RL   Am. J. Hum. Genet. 76:260-267(2005).
RN   [29]
RP   VARIANTS DD2 CYS-318 AND TRP-493.
RX   PubMed=17384968; DOI=10.1007/s00467-007-0454-x;
RA   Sekine T., Nozu K., Iyengar R., Fu X.J., Matsuo M., Tanaka R.,
RA   Iijima K., Matsui E., Harita Y., Inatomi J., Igarashi T.;
RT   "OCRL1 mutations in patients with Dent disease phenotype in Japan.";
RL   Pediatr. Nephrol. 22:975-980(2007).
RN   [30]
RP   VARIANT OCRL LYS-591.
RX   PubMed=19168822; DOI=10.1177/0883073808321047;
RA   Yuksel A., Karaca E., Albayram M.S.;
RT   "Magnetic resonance imaging, magnetic resonance spectroscopy, and
RT   facial dysmorphism in a case of Lowe syndrome with novel OCRL1 gene
RT   mutation.";
RL   J. Child Neurol. 24:93-96(2009).
RN   [31]
RP   VARIANTS OCRL SER-242; THR-274; ARG-277; CYS-318; CYS-337; ILE-361;
RP   GLY-372; TYR-373; PHE-374; ARG-414; ASN-451; GLY-457; LYS-468;
RP   GLY-468; LEU-495; HIS-499; ARG-503; LYS-591; VAL-742 DEL; PRO-797;
RP   LEU-801 AND ARG-891, AND VARIANTS DD2 HIS-354 AND LEU-799.
RX   PubMed=21031565; DOI=10.1002/humu.21391;
RA   Hichri H., Rendu J., Monnier N., Coutton C., Dorseuil O.,
RA   Poussou R.V., Baujat G., Blanchard A., Nobili F., Ranchin B.,
RA   Remesy M., Salomon R., Satre V., Lunardi J.;
RT   "From Lowe syndrome to Dent disease: correlations between mutations of
RT   the OCRL1 gene and clinical and biochemical phenotypes.";
RL   Hum. Mutat. 32:379-388(2011).
CC   -!- FUNCTION: Converts phosphatidylinositol 4,5-bisphosphate to
CC       phosphatidylinositol 4-phosphate. Also converts inositol 1,4,5-
CC       trisphosphate to inositol 1,4-bisphosphate and inositol 1,3,4,5-
CC       tetrakisphosphate to inositol 1,3,4-trisphosphate
CC       (PubMed:25869668, PubMed:7761412, PubMed:9430698). May function in
CC       lysosomal membrane trafficking by regulating the specific pool of
CC       phosphatidylinositol 4,5-bisphosphate that is associated with
CC       lysosomes. Involved in primary cilia assembly (PubMed:22228094,
CC       PubMed:22543976). {ECO:0000269|PubMed:22228094,
CC       ECO:0000269|PubMed:22543976, ECO:0000269|PubMed:25869668,
CC       ECO:0000269|PubMed:7761412, ECO:0000269|PubMed:9430698}.
CC   -!- CATALYTIC ACTIVITY: 1-phosphatidyl-1D-myo-inositol 4,5-
CC       bisphosphate + H(2)O = 1-phosphatidyl-1D-myo-inositol 4-phosphate
CC       + phosphate.
CC   -!- SUBUNIT: Interacts with APPL1, FAM109A/SES1 and FAM109B/SES2;
CC       APPL1-binding and FAM109A-binding are mutually exclusive.
CC       Interacts with clathrin heavy chain. Interacts with several Rab
CC       GTPases, at least RAB1B, RAB5A, RAB6A, RAB8A and RAB31; these
CC       interactions may play a dual role in targeting OCRL to the
CC       specific membranes and stimulating the phosphatase activity.
CC       Interaction with RAB8A modulates OCRL recruitment to cilia.
CC       Interacts with INPP5F (PubMed:25869668).
CC       {ECO:0000269|PubMed:17765681, ECO:0000269|PubMed:19536138,
CC       ECO:0000269|PubMed:20133602, ECO:0000269|PubMed:21233288,
CC       ECO:0000269|PubMed:21378754, ECO:0000269|PubMed:21666675,
CC       ECO:0000269|PubMed:22543976, ECO:0000269|PubMed:25869668}.
CC   -!- INTERACTION:
CC       Q00610:CLTC; NbExp=5; IntAct=EBI-6148898, EBI-354967;
CC       P11442:Cltc (xeno); NbExp=5; IntAct=EBI-6148898, EBI-397997;
CC       Q6ICB4:FAM109B; NbExp=4; IntAct=EBI-11749425, EBI-11081747;
CC       P61106:RAB14; NbExp=3; IntAct=EBI-6148898, EBI-1056404;
CC       P62820:RAB1A; NbExp=7; IntAct=EBI-6148898, EBI-716845;
CC       Q9H0U4:RAB1B; NbExp=2; IntAct=EBI-6148898, EBI-1045214;
CC       P20339:RAB5A; NbExp=10; IntAct=EBI-6148898, EBI-399437;
CC       P20340:RAB6A; NbExp=11; IntAct=EBI-6148898, EBI-1052826;
CC       P61006:RAB8A; NbExp=13; IntAct=EBI-6148898, EBI-722293;
CC       P63000:RAC1; NbExp=3; IntAct=EBI-6148898, EBI-413628;
CC   -!- SUBCELLULAR LOCATION: Cytoplasmic vesicle, phagosome membrane
CC       {ECO:0000250|UniProtKB:D3ZGS3}. Early endosome membrane
CC       {ECO:0000269|PubMed:25869668}. Membrane, clathrin-coated pit
CC       {ECO:0000269|PubMed:25869668}. Cell projection, cilium,
CC       photoreceptor outer segment {ECO:0000269|PubMed:22543976}. Cell
CC       projection, cilium {ECO:0000269|PubMed:22543976}. Cytoplasmic
CC       vesicle {ECO:0000250|UniProtKB:D3ZGS3}. Endosome
CC       {ECO:0000269|PubMed:25869668}. Golgi apparatus, trans-Golgi
CC       network {ECO:0000250|UniProtKB:D3ZGS3}. Note=Also found on
CC       macropinosomes. {ECO:0000269|PubMed:25869668}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=A;
CC         IsoId=Q01968-1; Sequence=Displayed;
CC       Name=B;
CC         IsoId=Q01968-2; Sequence=VSP_002681;
CC   -!- TISSUE SPECIFICITY: Brain, skeletal muscle, heart, kidney, lung,
CC       placenta and fibroblasts. Expressed in the retina and the retinal
CC       pigment epithelium. {ECO:0000269|PubMed:22543976}.
CC   -!- DOMAIN: The ASH (ASPM-SPD2-Hydin) and RhoGAP (Rho GTPase
CC       activating) domains form a single folding module. The ASH domain
CC       has an immunoglobulin-like fold, the Rho-GAP domain lacks the
CC       catalytic arginine and is catalytically inactive. The ASH-RhoGAP
CC       module regulates the majority of the protein-protein interactions
CC       currently described. The ASH domain mediates association with
CC       membrane-targeting Rab GTPases. The Rho-GAP domain interacts with
CC       the endocytic adapter APPL1, which is then displaced by FAM109A
CC       and FAM109B as endosomes mature. {ECO:0000269|PubMed:19536138}.
CC   -!- DISEASE: Lowe oculocerebrorenal syndrome (OCRL) [MIM:309000]: X-
CC       linked multisystem disorder affecting eyes, nervous system, and
CC       kidney. It is characterized by hydrophthalmia, cataract, mental
CC       retardation, vitamin D-resistant rickets, aminoaciduria, and
CC       reduced ammonia production by the kidney. Ocular abnormalities
CC       include cataract, glaucoma, microphthalmos, and decreased visual
CC       acuity. Developmental delay, hypotonia, behavior abnormalities,
CC       and areflexia are also present. Renal tubular involvement is
CC       characterized by impaired reabsorption of bicarbonate, amino
CC       acids, and phosphate. Musculoskeletal abnormalities such as joint
CC       hypermobility, dislocated hips, and fractures may develop as
CC       consequences of renal tubular acidosis and hypophosphatemia.
CC       Cataract is the only significant manifestation in carriers and is
CC       detected by slit-lamp examination. {ECO:0000269|PubMed:10767176,
CC       ECO:0000269|PubMed:10923037, ECO:0000269|PubMed:19168822,
CC       ECO:0000269|PubMed:20133602, ECO:0000269|PubMed:21031565,
CC       ECO:0000269|PubMed:21233288, ECO:0000269|PubMed:9199559,
CC       ECO:0000269|PubMed:9632163, ECO:0000269|PubMed:9682219,
CC       ECO:0000269|PubMed:9788721}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Dent disease 2 (DD2) [MIM:300555]: A renal disease
CC       belonging to the 'Dent disease complex', a group of disorders
CC       characterized by proximal renal tubular defect, hypercalciuria,
CC       nephrocalcinosis, and renal insufficiency. The spectrum of
CC       phenotypic features is remarkably similar in the various
CC       disorders, except for differences in the severity of bone
CC       deformities and renal impairment. Characteristic abnormalities
CC       include low-molecular-weight proteinuria and other features of
CC       Fanconi syndrome, such as glycosuria, aminoaciduria, and
CC       phosphaturia, but typically do not include proximal renal tubular
CC       acidosis. Progressive renal failure is common, as are
CC       nephrocalcinosis and kidney stones. {ECO:0000269|PubMed:15627218,
CC       ECO:0000269|PubMed:17384968, ECO:0000269|PubMed:21031565}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the inositol 1,4,5-trisphosphate 5-
CC       phosphatase type II family. {ECO:0000305}.
CC   -!- CAUTION: It is uncertain whether Met-1, Met-18 or Met-20 is the
CC       initiator. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA59964.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Lowe Syndrome mutation database;
CC       URL="http://research.nhgri.nih.gov/lowe/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M88162; AAA59964.2; ALT_INIT; mRNA.
DR   EMBL; U57627; AAB03839.2; -; mRNA.
DR   EMBL; AK293107; BAF85796.1; -; mRNA.
DR   EMBL; AL022162; CAI95695.1; -; Genomic_DNA.
DR   EMBL; AL138745; CAI95695.1; JOINED; Genomic_DNA.
DR   EMBL; AL662877; CAI95695.1; JOINED; Genomic_DNA.
DR   EMBL; AL022162; CAI95696.1; -; Genomic_DNA.
DR   EMBL; AL138745; CAI95696.1; JOINED; Genomic_DNA.
DR   EMBL; AL662877; CAI95696.1; JOINED; Genomic_DNA.
DR   EMBL; AL138745; CAI42615.1; -; Genomic_DNA.
DR   EMBL; AL022162; CAI42615.1; JOINED; Genomic_DNA.
DR   EMBL; AL662877; CAI42615.1; JOINED; Genomic_DNA.
DR   EMBL; AL138745; CAI42616.1; -; Genomic_DNA.
DR   EMBL; AL022162; CAI42616.1; JOINED; Genomic_DNA.
DR   EMBL; AL662877; CAI42616.1; JOINED; Genomic_DNA.
DR   EMBL; AL662877; CAI41087.1; -; Genomic_DNA.
DR   EMBL; AL022162; CAI41087.1; JOINED; Genomic_DNA.
DR   EMBL; AL138745; CAI41087.1; JOINED; Genomic_DNA.
DR   EMBL; AL662877; CAI41088.1; -; Genomic_DNA.
DR   EMBL; AL022162; CAI41088.1; JOINED; Genomic_DNA.
DR   EMBL; AL138745; CAI41088.1; JOINED; Genomic_DNA.
DR   EMBL; Z73496; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471107; EAX11831.1; -; Genomic_DNA.
DR   EMBL; CH471107; EAX11832.1; -; Genomic_DNA.
DR   EMBL; BC130612; AAI30613.1; -; mRNA.
DR   EMBL; BC144106; AAI44107.1; -; mRNA.
DR   EMBL; S62085; AAB26926.1; -; mRNA.
DR   CCDS; CCDS35393.1; -. [Q01968-1]
DR   CCDS; CCDS35394.1; -. [Q01968-2]
DR   PIR; S29069; S29069.
DR   RefSeq; NP_000267.2; NM_000276.3. [Q01968-1]
DR   RefSeq; NP_001578.2; NM_001587.3. [Q01968-2]
DR   UniGene; Hs.126357; -.
DR   PDB; 2KIE; NMR; -; A=1-119.
DR   PDB; 2QV2; X-ray; 2.40 A; A=564-901.
DR   PDB; 3QBT; X-ray; 2.00 A; B/D/F/H=540-678.
DR   PDB; 3QIS; X-ray; 2.30 A; A=536-901.
DR   PDB; 4CMN; X-ray; 3.13 A; A=215-560.
DR   PDBsum; 2KIE; -.
DR   PDBsum; 2QV2; -.
DR   PDBsum; 3QBT; -.
DR   PDBsum; 3QIS; -.
DR   PDBsum; 4CMN; -.
DR   ProteinModelPortal; Q01968; -.
DR   SMR; Q01968; -.
DR   BioGrid; 111006; 39.
DR   DIP; DIP-45092N; -.
DR   IntAct; Q01968; 45.
DR   MINT; MINT-5004450; -.
DR   STRING; 9606.ENSP00000360154; -.
DR   SwissLipids; SLP:000001182; -.
DR   DEPOD; Q01968; -.
DR   iPTMnet; Q01968; -.
DR   PhosphoSitePlus; Q01968; -.
DR   BioMuta; OCRL; -.
DR   DMDM; 67477390; -.
DR   EPD; Q01968; -.
DR   MaxQB; Q01968; -.
DR   PaxDb; Q01968; -.
DR   PeptideAtlas; Q01968; -.
DR   PRIDE; Q01968; -.
DR   TopDownProteomics; Q01968-2; -. [Q01968-2]
DR   Ensembl; ENST00000357121; ENSP00000349635; ENSG00000122126. [Q01968-2]
DR   Ensembl; ENST00000371113; ENSP00000360154; ENSG00000122126. [Q01968-1]
DR   GeneID; 4952; -.
DR   KEGG; hsa:4952; -.
DR   UCSC; uc004euq.4; human. [Q01968-1]
DR   CTD; 4952; -.
DR   DisGeNET; 4952; -.
DR   GeneCards; OCRL; -.
DR   GeneReviews; OCRL; -.
DR   HGNC; HGNC:8108; OCRL.
DR   HPA; HPA012495; -.
DR   MalaCards; OCRL; -.
DR   MIM; 300535; gene.
DR   MIM; 300555; phenotype.
DR   MIM; 309000; phenotype.
DR   neXtProt; NX_Q01968; -.
DR   OpenTargets; ENSG00000122126; -.
DR   Orphanet; 93623; Dent disease type 2.
DR   Orphanet; 534; Oculocerebrorenal syndrome.
DR   PharmGKB; PA31896; -.
DR   eggNOG; KOG0565; Eukaryota.
DR   eggNOG; COG5411; LUCA.
DR   GeneTree; ENSGT00760000119075; -.
DR   HOGENOM; HOG000008071; -.
DR   HOVERGEN; HBG000070; -.
DR   InParanoid; Q01968; -.
DR   KO; K01099; -.
DR   OMA; IPDEEHC; -.
DR   OrthoDB; EOG091G02KE; -.
DR   PhylomeDB; Q01968; -.
DR   TreeFam; TF317034; -.
DR   BioCyc; MetaCyc:HS04546-MONOMER; -.
DR   BRENDA; 3.1.3.36; 2681.
DR   Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane.
DR   Reactome; R-HSA-1660514; Synthesis of PIPs at the Golgi membrane.
DR   Reactome; R-HSA-1855183; Synthesis of IP2, IP, and Ins in the cytosol.
DR   Reactome; R-HSA-1855204; Synthesis of IP3 and IP4 in the cytosol.
DR   Reactome; R-HSA-194840; Rho GTPase cycle.
DR   Reactome; R-HSA-432722; Golgi Associated Vesicle Biogenesis.
DR   Reactome; R-HSA-8856828; Clathrin-mediated endocytosis.
DR   SignaLink; Q01968; -.
DR   EvolutionaryTrace; Q01968; -.
DR   GeneWiki; OCRL; -.
DR   GenomeRNAi; 4952; -.
DR   PRO; PR:Q01968; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000122126; -.
DR   CleanEx; HS_INPP5F; -.
DR   Genevisible; Q01968; HS.
DR   GO; GO:0005905; C:clathrin-coated pit; IEA:UniProtKB-SubCell.
DR   GO; GO:0030136; C:clathrin-coated vesicle; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:FlyBase.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005769; C:early endosome; IDA:UniProtKB.
DR   GO; GO:0031901; C:early endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005795; C:Golgi stack; TAS:ProtInc.
DR   GO; GO:0005798; C:Golgi-associated vesicle; TAS:ProtInc.
DR   GO; GO:0005634; C:nucleus; IDA:FlyBase.
DR   GO; GO:0030670; C:phagocytic vesicle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0001750; C:photoreceptor outer segment; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:FlyBase.
DR   GO; GO:0005802; C:trans-Golgi network; IDA:FlyBase.
DR   GO; GO:0005096; F:GTPase activator activity; IDA:FlyBase.
DR   GO; GO:0052745; F:inositol phosphate phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0052659; F:inositol-1,3,4,5-tetrakisphosphate 5-phosphatase activity; TAS:Reactome.
DR   GO; GO:0052658; F:inositol-1,4,5-trisphosphate 5-phosphatase activity; TAS:Reactome.
DR   GO; GO:0034596; F:phosphatidylinositol phosphate 4-phosphatase activity; TAS:Reactome.
DR   GO; GO:0043813; F:phosphatidylinositol-3,5-bisphosphate 5-phosphatase activity; TAS:Reactome.
DR   GO; GO:0004439; F:phosphatidylinositol-4,5-bisphosphate 5-phosphatase activity; TAS:Reactome.
DR   GO; GO:0048365; F:Rac GTPase binding; IPI:FlyBase.
DR   GO; GO:0060271; P:cilium assembly; IMP:UniProtKB.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0043647; P:inositol phosphate metabolic process; TAS:Reactome.
DR   GO; GO:0006629; P:lipid metabolic process; TAS:ProtInc.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0006661; P:phosphatidylinositol biosynthetic process; TAS:Reactome.
DR   GO; GO:0046856; P:phosphatidylinositol dephosphorylation; IEA:Ensembl.
DR   GO; GO:0043087; P:regulation of GTPase activity; IDA:FlyBase.
DR   GO; GO:0051056; P:regulation of small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0007165; P:signal transduction; IEA:InterPro.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.60.10.10; -; 1.
DR   InterPro; IPR005135; Endo/exonuclease/phosphatase.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR000300; IPPc.
DR   InterPro; IPR031995; OCRL_clath-bd.
DR   InterPro; IPR008936; Rho_GTPase_activation_prot.
DR   InterPro; IPR000198; RhoGAP_dom.
DR   Pfam; PF03372; Exo_endo_phos; 1.
DR   Pfam; PF16726; OCRL_clath_bd; 1.
DR   Pfam; PF00620; RhoGAP; 1.
DR   SMART; SM00128; IPPc; 1.
DR   SMART; SM00324; RhoGAP; 1.
DR   SUPFAM; SSF48350; SSF48350; 2.
DR   SUPFAM; SSF56219; SSF56219; 1.
DR   PROSITE; PS50238; RHOGAP; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cataract; Cell projection;
KW   Ciliopathy; Cilium; Cilium biogenesis/degradation; Coated pit;
KW   Complete proteome; Cytoplasmic vesicle; Disease mutation; Endosome;
KW   Golgi apparatus; Hydrolase; Membrane; Reference proteome.
FT   CHAIN         1    901       Inositol polyphosphate 5-phosphatase
FT                                OCRL-1.
FT                                /FTId=PRO_0000209721.
FT   DOMAIN        1    119       PH.
FT   DOMAIN      721    901       Rho-GAP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00172}.
FT   REGION      237    563       5-phosphatase.
FT   REGION      564    678       ASH.
FT   MOTIF        73     77       Clathrin box 1.
FT   MOTIF       702    706       Clathrin box 2.
FT   VAR_SEQ     707    714       Missing (in isoform B).
FT                                {ECO:0000303|PubMed:1321346,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_002681.
FT   VARIANT     242    242       F -> S (in OCRL; dbSNP:rs137853828).
FT                                {ECO:0000269|PubMed:21031565}.
FT                                /FTId=VAR_064773.
FT   VARIANT     274    274       I -> T (in OCRL; dbSNP:rs137853829).
FT                                {ECO:0000269|PubMed:21031565}.
FT                                /FTId=VAR_064774.
FT   VARIANT     277    277       Q -> R (in OCRL; dbSNP:rs137853830).
FT                                {ECO:0000269|PubMed:21031565}.
FT                                /FTId=VAR_064775.
FT   VARIANT     318    318       R -> C (in DD2 and OCRL;
FT                                dbSNP:rs137853263).
FT                                {ECO:0000269|PubMed:15627218,
FT                                ECO:0000269|PubMed:17384968,
FT                                ECO:0000269|PubMed:21031565}.
FT                                /FTId=VAR_022698.
FT   VARIANT     337    337       R -> C (in OCRL; associated with I-361;
FT                                dbSNP:rs137853831).
FT                                {ECO:0000269|PubMed:21031565}.
FT                                /FTId=VAR_064776.
FT   VARIANT     337    337       R -> P (in OCRL).
FT                                /FTId=VAR_010169.
FT   VARIANT     354    354       N -> H (in DD2; dbSNP:rs137853833).
FT                                {ECO:0000269|PubMed:21031565}.
FT                                /FTId=VAR_064777.
FT   VARIANT     357    357       G -> E (in OCRL; uncertain pathological
FT                                significance; dbSNP:rs137853854).
FT                                {ECO:0000269|PubMed:10923037}.
FT                                /FTId=VAR_010170.
FT   VARIANT     361    361       R -> I (in OCRL; associated with C-337;
FT                                dbSNP:rs137853832).
FT                                {ECO:0000269|PubMed:21031565}.
FT                                /FTId=VAR_064778.
FT   VARIANT     367    367       Missing (in OCRL).
FT                                {ECO:0000269|PubMed:9199559}.
FT                                /FTId=VAR_010171.
FT   VARIANT     372    372       V -> G (in OCRL; dbSNP:rs137853834).
FT                                {ECO:0000269|PubMed:21031565}.
FT                                /FTId=VAR_010172.
FT   VARIANT     373    373       N -> Y (in OCRL; dbSNP:rs137853835).
FT                                {ECO:0000269|PubMed:21031565}.
FT                                /FTId=VAR_064779.
FT   VARIANT     374    374       S -> F (in OCRL; dbSNP:rs137853836).
FT                                {ECO:0000269|PubMed:21031565}.
FT                                /FTId=VAR_064780.
FT   VARIANT     375    375       H -> Y (in OCRL; dbSNP:rs137853848).
FT                                {ECO:0000269|PubMed:9682219}.
FT                                /FTId=VAR_010173.
FT   VARIANT     414    414       H -> R (in OCRL; dbSNP:rs137853837).
FT                                {ECO:0000269|PubMed:21031565}.
FT                                /FTId=VAR_064781.
FT   VARIANT     421    421       G -> E (in OCRL; dbSNP:rs137853855).
FT                                {ECO:0000269|PubMed:10923037}.
FT                                /FTId=VAR_010174.
FT   VARIANT     424    424       N -> D (in OCRL; dbSNP:rs137853856).
FT                                {ECO:0000269|PubMed:10923037}.
FT                                /FTId=VAR_010175.
FT   VARIANT     451    451       D -> G (in OCRL; dbSNP:rs137853850).
FT                                {ECO:0000269|PubMed:9199559}.
FT                                /FTId=VAR_010176.
FT   VARIANT     451    451       D -> N (in OCRL; dbSNP:rs137853838).
FT                                {ECO:0000269|PubMed:21031565}.
FT                                /FTId=VAR_064782.
FT   VARIANT     457    457       R -> G (in OCRL; dbSNP:rs137853839).
FT                                {ECO:0000269|PubMed:21031565}.
FT                                /FTId=VAR_064783.
FT   VARIANT     463    463       F -> S (in OCRL; dbSNP:rs137853851).
FT                                {ECO:0000269|PubMed:9199559}.
FT                                /FTId=VAR_010177.
FT   VARIANT     468    468       E -> G (in OCRL; dbSNP:rs137853841).
FT                                {ECO:0000269|PubMed:21031565}.
FT                                /FTId=VAR_064784.
FT   VARIANT     468    468       E -> K (in OCRL; dbSNP:rs137853840).
FT                                {ECO:0000269|PubMed:21031565}.
FT                                /FTId=VAR_064785.
FT   VARIANT     478    479       Missing (in OCRL).
FT                                /FTId=VAR_023957.
FT   VARIANT     479    479       Y -> C (in DD2; dbSNP:rs137853262).
FT                                {ECO:0000269|PubMed:15627218}.
FT                                /FTId=VAR_022699.
FT   VARIANT     493    493       R -> W (in DD2; dbSNP:rs137853846).
FT                                {ECO:0000269|PubMed:17384968}.
FT                                /FTId=VAR_064786.
FT   VARIANT     495    495       P -> L (in OCRL).
FT                                {ECO:0000269|PubMed:21031565}.
FT                                /FTId=VAR_064787.
FT   VARIANT     498    498       C -> Y (in OCRL; dbSNP:rs137853857).
FT                                {ECO:0000269|PubMed:10923037}.
FT                                /FTId=VAR_010178.
FT   VARIANT     499    499       D -> H (in OCRL; dbSNP:rs137853842).
FT                                {ECO:0000269|PubMed:21031565}.
FT                                /FTId=VAR_064788.
FT   VARIANT     500    500       R -> G (in OCRL; dbSNP:rs398123287).
FT                                /FTId=VAR_010179.
FT   VARIANT     500    500       R -> Q (in OCRL; dbSNP:rs137853260).
FT                                {ECO:0000269|PubMed:10767176,
FT                                ECO:0000269|PubMed:9632163,
FT                                ECO:0000269|PubMed:9682219}.
FT                                /FTId=VAR_010180.
FT   VARIANT     503    503       W -> R (in OCRL; dbSNP:rs137853843).
FT                                {ECO:0000269|PubMed:21031565}.
FT                                /FTId=VAR_064789.
FT   VARIANT     508    508       V -> D (in OCRL; dbSNP:rs137853849).
FT                                {ECO:0000269|PubMed:9682219}.
FT                                /FTId=VAR_010181.
FT   VARIANT     513    513       Y -> C (in OCRL; dbSNP:rs137853847).
FT                                {ECO:0000269|PubMed:9682219}.
FT                                /FTId=VAR_010182.
FT   VARIANT     522    522       S -> R (in OCRL; dbSNP:rs137853853).
FT                                {ECO:0000269|PubMed:9788721}.
FT                                /FTId=VAR_010183.
FT   VARIANT     524    524       H -> Q (in OCRL; dbSNP:rs137853261).
FT                                {ECO:0000269|PubMed:9632163}.
FT                                /FTId=VAR_010184.
FT   VARIANT     524    524       H -> R (in OCRL; dbSNP:rs137853852).
FT                                {ECO:0000269|PubMed:9199559}.
FT                                /FTId=VAR_010185.
FT   VARIANT     526    526       P -> L (in OCRL; dbSNP:rs137853858).
FT                                {ECO:0000269|PubMed:10767176}.
FT                                /FTId=VAR_023958.
FT   VARIANT     533    533       I -> S (in OCRL).
FT                                /FTId=VAR_010187.
FT   VARIANT     591    591       N -> K (in OCRL; dbSNP:rs137853844).
FT                                {ECO:0000269|PubMed:19168822,
FT                                ECO:0000269|PubMed:21031565}.
FT                                /FTId=VAR_064790.
FT   VARIANT     742    742       Missing (in OCRL).
FT                                {ECO:0000269|PubMed:21031565}.
FT                                /FTId=VAR_064791.
FT   VARIANT     768    768       I -> N (in OCRL; uncertain pathological
FT                                significance; abolishes FAM109A-,
FT                                FAM109B- and APPL1-binding).
FT                                {ECO:0000269|PubMed:20133602,
FT                                ECO:0000269|PubMed:21233288}.
FT                                /FTId=VAR_010188.
FT   VARIANT     797    797       A -> P (in OCRL; uncertain pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20133602,
FT                                ECO:0000269|PubMed:21031565}.
FT                                /FTId=VAR_010189.
FT   VARIANT     799    799       P -> L (in DD2).
FT                                {ECO:0000269|PubMed:21031565}.
FT                                /FTId=VAR_064792.
FT   VARIANT     801    801       P -> L (in OCRL).
FT                                {ECO:0000269|PubMed:21031565}.
FT                                /FTId=VAR_064793.
FT   VARIANT     891    891       L -> R (in OCRL; dbSNP:rs137853845).
FT                                {ECO:0000269|PubMed:21031565}.
FT                                /FTId=VAR_064794.
FT   MUTAGEN     422    422       D->A: Does not affect interaction with
FT                                RAB8A. {ECO:0000269|PubMed:22543976}.
FT   MUTAGEN     499    499       D->A: Does not affect interaction with
FT                                RAB8A. {ECO:0000269|PubMed:22543976}.
FT   MUTAGEN     668    668       F->V: Does not interact with RAB8A. Does
FT                                not localize to cilia.
FT                                {ECO:0000269|PubMed:22543976}.
FT   CONFLICT    180    180       P -> L (in Ref. 4; BAF85796).
FT                                {ECO:0000305}.
FT   CONFLICT    321    321       G -> E (in Ref. 7; AAI44107).
FT                                {ECO:0000305}.
FT   STRAND       10     21       {ECO:0000244|PDB:2KIE}.
FT   STRAND       24     35       {ECO:0000244|PDB:2KIE}.
FT   STRAND       38     45       {ECO:0000244|PDB:2KIE}.
FT   STRAND       52     57       {ECO:0000244|PDB:2KIE}.
FT   STRAND       59     61       {ECO:0000244|PDB:2KIE}.
FT   STRAND       63     70       {ECO:0000244|PDB:2KIE}.
FT   HELIX        76     78       {ECO:0000244|PDB:2KIE}.
FT   STRAND       80     90       {ECO:0000244|PDB:2KIE}.
FT   STRAND       94     98       {ECO:0000244|PDB:2KIE}.
FT   HELIX       101    118       {ECO:0000244|PDB:2KIE}.
FT   HELIX       222    229       {ECO:0000244|PDB:4CMN}.
FT   HELIX       231    234       {ECO:0000244|PDB:4CMN}.
FT   STRAND      235    248       {ECO:0000244|PDB:4CMN}.
FT   HELIX       259    262       {ECO:0000244|PDB:4CMN}.
FT   STRAND      265    267       {ECO:0000244|PDB:4CMN}.
FT   STRAND      270    277       {ECO:0000244|PDB:4CMN}.
FT   HELIX       283    286       {ECO:0000244|PDB:4CMN}.
FT   HELIX       292    304       {ECO:0000244|PDB:4CMN}.
FT   STRAND      311    319       {ECO:0000244|PDB:4CMN}.
FT   STRAND      322    329       {ECO:0000244|PDB:4CMN}.
FT   HELIX       332    335       {ECO:0000244|PDB:4CMN}.
FT   STRAND      336    345       {ECO:0000244|PDB:4CMN}.
FT   HELIX       348    350       {ECO:0000244|PDB:4CMN}.
FT   STRAND      355    364       {ECO:0000244|PDB:4CMN}.
FT   STRAND      367    375       {ECO:0000244|PDB:4CMN}.
FT   HELIX       383    396       {ECO:0000244|PDB:4CMN}.
FT   HELIX       411    413       {ECO:0000244|PDB:4CMN}.
FT   STRAND      414    422       {ECO:0000244|PDB:4CMN}.
FT   HELIX       432    440       {ECO:0000244|PDB:4CMN}.
FT   HELIX       444    448       {ECO:0000244|PDB:4CMN}.
FT   HELIX       452    458       {ECO:0000244|PDB:4CMN}.
FT   STRAND      461    463       {ECO:0000244|PDB:4CMN}.
FT   STRAND      483    486       {ECO:0000244|PDB:4CMN}.
FT   STRAND      489    491       {ECO:0000244|PDB:4CMN}.
FT   STRAND      499    504       {ECO:0000244|PDB:4CMN}.
FT   STRAND      506    510       {ECO:0000244|PDB:4CMN}.
FT   STRAND      521    524       {ECO:0000244|PDB:4CMN}.
FT   STRAND      527    538       {ECO:0000244|PDB:4CMN}.
FT   HELIX       541    548       {ECO:0000244|PDB:3QBT}.
FT   HELIX       553    560       {ECO:0000244|PDB:3QBT}.
FT   STRAND      565    568       {ECO:0000244|PDB:3QBT}.
FT   STRAND      571    577       {ECO:0000244|PDB:3QBT}.
FT   STRAND      583    591       {ECO:0000244|PDB:3QBT}.
FT   STRAND      593    595       {ECO:0000244|PDB:3QBT}.
FT   STRAND      597    602       {ECO:0000244|PDB:3QBT}.
FT   STRAND      608    611       {ECO:0000244|PDB:3QBT}.
FT   STRAND      615    619       {ECO:0000244|PDB:3QBT}.
FT   STRAND      621    624       {ECO:0000244|PDB:3QBT}.
FT   STRAND      629    636       {ECO:0000244|PDB:3QBT}.
FT   HELIX       640    648       {ECO:0000244|PDB:3QBT}.
FT   STRAND      649    651       {ECO:0000244|PDB:3QBT}.
FT   STRAND      655    661       {ECO:0000244|PDB:3QBT}.
FT   STRAND      666    675       {ECO:0000244|PDB:3QBT}.
FT   HELIX       684    689       {ECO:0000244|PDB:3QIS}.
FT   HELIX       700    702       {ECO:0000244|PDB:2QV2}.
FT   HELIX       736    748       {ECO:0000244|PDB:3QIS}.
FT   TURN        753    757       {ECO:0000244|PDB:3QIS}.
FT   HELIX       762    774       {ECO:0000244|PDB:3QIS}.
FT   HELIX       784    797       {ECO:0000244|PDB:3QIS}.
FT   HELIX       805    814       {ECO:0000244|PDB:3QIS}.
FT   HELIX       818    826       {ECO:0000244|PDB:3QIS}.
FT   HELIX       830    847       {ECO:0000244|PDB:3QIS}.
FT   HELIX       850    853       {ECO:0000244|PDB:3QIS}.
FT   HELIX       857    868       {ECO:0000244|PDB:3QIS}.
FT   HELIX       873    875       {ECO:0000244|PDB:2QV2}.
FT   HELIX       883    895       {ECO:0000244|PDB:3QIS}.
SQ   SEQUENCE   901 AA;  104205 MW;  476BFCCC3655C1FE CRC64;
     MEPPLPVGAQ PLATVEGMEM KGPLREPCAL TLAQRNGQYE LIIQLHEKEQ HVQDIIPINS
     HFRCVQEAEE TLLIDIASNS GCKIRVQGDW IRERRFEIPD EEHCLKFLSA VLAAQKAQSQ
     LLVPEQKDSS SWYQKLDTKD KPSVFSGLLG FEDNFSSMNL DKKINSQNQP TGIHREPPPP
     PFSVNKMLPR EKEASNKEQP KVTNTMRKLF VPNTQSGQRE GLIKHILAKR EKEYVNIQTF
     RFFVGTWNVN GQSPDSGLEP WLNCDPNPPD IYCIGFQELD LSTEAFFYFE SVKEQEWSMA
     VERGLHSKAK YKKVQLVRLV GMMLLIFARK DQCRYIRDIA TETVGTGIMG KMGNKGGVAV
     RFVFHNTTFC IVNSHLAAHV EDFERRNQDY KDICARMSFV VPNQTLPQLN IMKHEVVIWL
     GDLNYRLCMP DANEVKSLIN KKDLQRLLKF DQLNIQRTQK KAFVDFNEGE IKFIPTYKYD
     SKTDRWDSSG KCRVPAWCDR ILWRGTNVNQ LNYRSHMELK TSDHKPVSAL FHIGVKVVDE
     RRYRKVFEDS VRIMDRMEND FLPSLELSRR EFVFENVKFR QLQKEKFQIS NNGQVPCHFS
     FIPKLNDSQY CKPWLRAEPF EGYLEPNETV DISLDVYVSK DSVTILNSGE DKIEDILVLH
     LDRGKDYFLT ISGNYLPSCF GTSLEALCRM KRPIREVPVT KLIDLEEDSF LEKEKSLLQM
     VPLDEGASER PLQVPKEIWL LVDHLFKYAC HQEDLFQTPG MQEELQQIID CLDTSIPETI
     PGSNHSVAEA LLIFLEALPE PVICYELYQR CLDSAYDPRI CRQVISQLPR CHRNVFRYLM
     AFLRELLKFS EYNSVNANMI ATLFTSLLLR PPPNLMARQT PSDRQRAIQF LLGFLLGSEE
     D
//
